| Histone deacetylases and cancer: causes and therapies PA Marks, RA Rifkind, VM Richon, R Breslow, T Miller, WK Kelly Nature Reviews Cancer 1 (3), 194-202, 2001 | 2478 | 2001 |
| Histone deacetylase inhibitors TA Miller, DJ Witter, S Belvedere Journal of medicinal chemistry 46 (24), 5097-5116, 2003 | 787 | 2003 |
| Histone deacetylase inhibitors. PA Marks, VM Richon, T Miller, WK Kelly Advances in cancer research 91, 137-168, 2004 | 655 | 2004 |
| Histone deacetylases PA Marks, T Miller, VM Richon Current opinion in pharmacology 3 (4), 344-351, 2003 | 564 | 2003 |
| Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1: 2) JL Methot, PK Chakravarty, M Chenard, J Close, JC Cruz, WK Dahlberg, ... Bioorganic & medicinal chemistry letters 18 (3), 973-978, 2008 | 217 | 2008 |
| Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof R Breslow, S Belvedere, L Gershell, TA Miller, PA Marks, VM Richon, ... US Patent 6,511,990, 2003 | 136 | 2003 |
| Optimization of biaryl selective HDAC1&2 inhibitors (SHI-1: 2) DJ Witter, P Harrington, KJ Wilson, M Chenard, JC Fleming, B Haines, ... Bioorganic & medicinal chemistry letters 18 (2), 726-731, 2008 | 135 | 2008 |
| Histone deacetylase inhibitors: development as cancer therapy PA Marks, VM Richon, WK Kelly, JH Chiao, T Miller Reversible Protein Acetylation: Novartis Foundation Symposium 259 259, 269-284, 2004 | 111 | 2004 |
| Methods of treating mesothelioma with suberoylanilide hydroxamic acid NG Bacopoulos, JH Chiao, TA Miller, CM Paradise, VM Richon US Patent 7,148,257, 2006 | 107 | 2006 |
| Combination methods of treating cancer N Bacopoulos, J Chiao, P Marks, T Miller, C Paradise, V Richon, R Rifkind US Patent App. 10/567,953, 2007 | 97 | 2007 |
| Methods of treating cancer with HDAC inhibitors N Bacopoulos, J Chiao, T Miller, C Paradise, V Richon US Patent App. 10/665,079, 2004 | 86 | 2004 |
| Polymorphs of suberoylanilide hydroxamic acid TA Miller, VM Richon, JH Chiao US Patent 7,456,219, 2008 | 84 | 2008 |
| Methods of treating cancer with HDAC inhibitors JH Chiao, NG Bacopoulos, TA Miller, CM Paradise, VM Richon US Patent 7,399,787, 2008 | 83 | 2008 |
| Synthesis and Structure− Activity profiles of A-homoestranes, the estratropones TA Miller, AL Bulman, CD Thompson, ME Garst, TL Macdonald Journal of medicinal chemistry 40 (23), 3836-3841, 1997 | 69 | 1997 |
| Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids CD Thompson, MT Barthen, DW Hopper, TA Miller, M Quigg, C Hudspeth, ... Epilepsia 40 (6), 769-776, 1999 | 68 | 1999 |
| Methods of treating cancer with HDAC inhibitors N Bacopoulos, J Chiao, T Miller, C Paradise, V Richon US Patent App. 10/692,523, 2004 | 64 | 2004 |
| Design of novel histone deacetylase inhibitors P Siliphaivanh, P Harrington, DJ Witter, K Otte, P Tempest, S Kattar, ... Bioorganic & medicinal chemistry letters 17 (16), 4619-4624, 2007 | 63 | 2007 |
| The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors CL Hamblett, JL Methot, DM Mampreian, DL Sloman, MG Stanton, ... Bioorganic & medicinal chemistry letters 17 (19), 5300-5309, 2007 | 61 | 2007 |
| Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC inhibitors S Belvedere, DJ Witter, J Yan, JP Secrist, V Richon, TA Miller Bioorganic & medicinal chemistry letters 17 (14), 3969-3971, 2007 | 59 | 2007 |
| Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof R Breslow, S Belvedere, L Gershell, TA Miller, PA Marks, VM Richon, ... US Patent 7,126,001, 2006 | 59 | 2006 |
Solomon KattarMerck在 merck.com 的电子邮件经过验证
